4D Molecular Therapeutics, Inc. ((FDMT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4D Molecular Therapeutics, Inc. is conducting a clinical study titled ‘A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration.’ The study aims to evaluate the safety and efficacy of 4D-150, a gene therapy, in treating wet age-related macular degeneration (AMD), a leading cause of vision loss. This research is significant as it explores a novel treatment approach for a condition with limited therapeutic options.
The intervention being tested is 4D-150, an AAV-based gene therapy designed to target VEGF-C and encode aflibercept. It is administered as an intravitreal (IVT) injection and aims to provide a long-term treatment solution for wet AMD by reducing the need for frequent anti-VEGF injections.
The study follows an interventional design with randomized allocation and a sequential intervention model. It includes both open-label and single-masked phases, focusing on treatment as the primary purpose. The study involves multiple cohorts to assess different dose levels and treatment regimens.
The study began on January 5, 2022, and is currently recruiting participants. The primary completion date is yet to be announced, with the last update recorded on September 9, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential data availability.
The update on this study could influence 4D Molecular Therapeutics’ stock performance by attracting investor interest due to the potential breakthrough in treating wet AMD. The gene therapy market is competitive, with several companies exploring similar innovations, which could impact investor sentiment and market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.